We are live on
!
Find out more
TCM
Towercrest Capital Management Portfolio holdings
AUM
$642M
1-Year Est. Return
11.71%
This Fund
S&P 500
This Quarter
Est. Return
-5.73%
1 Year Est. Return
+11.71%
3 Year Est. Return
+31.42%
5 Year Est. Return
+23.73%
10 Year Est. Return
+78.8%
AUM
$513M
AUM Growth
-$33.8M
(-6.2%)
Cap. Flow
-$1.83M
Cap. Flow
% of AUM
-0.36%
Top 10 Holdings %
Top 10 Hldgs %
46.41%
Holding
94
New
1
Increased
35
Reduced
27
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
+$5.37M |
| 2 |
PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
|
+$1.71M |
| 3 |
Schwab US Aggregate Bond ETF
SCHZ
|
+$1.05M |
| 4 |
Schwab US Dividend Equity ETF
SCHD
|
+$860K |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$832K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco Emerging Markets Sovereign Debt ETF
PCY
|
+$5.38M |
| 2 |
iShares Floating Rate Bond ETF
FLOT
|
+$1.8M |
| 3 |
Schwab US Large- Cap ETF
SCHX
|
+$1.46M |
| 4 |
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
|
+$752K |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$745K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 2.94% |
| 2 | Communication Services | 0.83% |
| 3 | Healthcare | 0.76% |
| 4 | Financials | 0.48% |
| 5 | Consumer Staples | 0.34% |
Similar funds
APC
CFM
RR
GECH
WHGAM
OP
PCM
CRCM
Towercrest Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Towercrest Capital Management held 94 positions worth $513M, down 6.2% from $547M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Trading was light in Q1 2022: portfolio turnover was 4.3%. Towercrest Capital Management opened 1 new position and exited 3, leaving the 94-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 2.9% of assets, up from 2.8% a quarter earlier, followed by Communication Services and Healthcare.
- Towercrest Capital Management's largest Q1 2022 buy was PhaseBio Pharmaceuticals, Inc. Common Stock: 1,051,940 shares worth $1.39M.
- Towercrest Capital Management added most to iShares JPMorgan USD Emerging Markets Bond ETF in Q1 2022, an estimated $5.37M increase.
- Towercrest Capital Management's biggest Q1 2022 reduction was Invesco Emerging Markets Sovereign Debt ETF, cutting an estimated $5.38M.
- Towercrest Capital Management fully exited State Street DoubleLine Total Return Tactical ETF in Q1 2022, selling an estimated $211K.
- Towercrest Capital Management's ten largest holdings make up 46% of its $513M portfolio in Q1 2022.
- Towercrest Capital Management opened 1 new position and closed 3 in Q1 2022.
- Towercrest Capital Management's portfolio value fell 6.2% quarter-over-quarter to $513M.
Based on Towercrest Capital Management's 13F filing for Q1 2022, filed 11 May 2022.